Handelsbanken Fonder Ab Halozyme Therapeutics, Inc. Transaction History
Handelsbanken Fonder Ab
- $24.3 Billion
- Q1 2025
A detailed history of Handelsbanken Fonder Ab transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 266,069 shares of HALO stock, worth $17.1 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
266,069
Previous 516,469
48.48%
Holding current value
$17.1 Million
Previous $24.7 Million
31.24%
% of portfolio
0.07%
Previous 0.09%
Shares
15 transactions
Others Institutions Holding HALO
# of Institutions
600Shares Held
127MCall Options Held
408KPut Options Held
388K-
Black Rock Inc. New York, NY17.6MShares$1.13 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.2MShares$787 Million0.01% of portfolio
-
State Street Corp Boston, MA5.94MShares$381 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA3.47MShares$223 Million0.03% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.4MShares$218 Million3.92% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.95B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...